关于公司
Kymab, based in Cambridge, UK, is working independently and with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high-quality human antibodies for treating challenging diseases. We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases, with clinical studies expected to begin in 2017.
GB
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论